Also found in: Wikipedia.


A nonionic structural analog of gadolinium DPTA; used as a paramagnetic contrast medium in magnetic resonance imaging.
References in periodicals archive ?
5 mmol/ml) for MRI Inj Gadodiamide 10 ml prefilled Syringes
4 ms; matrix, 352; FOV, 340; flip angle, 10[degrees]; slice thickness, 1 mm) was used before and repeated 6 times after contrast administration Following gadolinium contrast agents were used: gadoterate dimeglumine (Dotarem [R], Guerbet) for 57 cases, gadobutrol (Gadovist[R], Bayer Healthcare) for 31 cases and gadodiamide (Omniscan[R], GE Healthcare) for 28 cases.
According to stability constants and kinetic measurements, the most stable GBCA is the ionic-macrocyclic chelate Gd-DOTA and the least stable agents are the nonionic linear chelates gadodiamide and gadoversetamide [17-20].
Also, Group II gadolinium-based agents, such as gadoteridol and gadobenate dimeglumine, should be used rather than Group I agents like gadodiamide and gadopentatate dimeglumine, which are associated with the greatest number of NSF cases.
Closely related diagnostic agents are gadobenate dimeglumine (MultiHance), gadodiamide (Omniscan), gadofosveset (Ablavar), gadopentetate dimeglumine (Magnevist), gadoteridol (Prohance), and gadoversetamide (OptiMARK).
Patients At higher risk * Patients with CKD 4 and 5 (GFR < 30 ml/min) * Patients on dialysis * Patients with acute kidney insufficiency At lower risk * Patients with CKD 3 (GFR 30 - 59 ml/min) Not at risk of NSF * Patients with stable GFR > 60 ml/min) Highest risk of NSF Gadopentetate dimeglumine (Magnevist plus generic products) Gadodiamide (Omniscan) Gadoversetamide (Optimark) Recommendations for These agents are CONTRA-INDICATED high-risk group in: * patients with CKD 4 and 5 (GFR <30 ml/min), including those on dialysis * acute renal insufficiency * pregnant women * neonates These agents should be used with CAUTION in: * patients with CKD 3 (GFR 30 - 60 ml/min) * There should be at least 7 days between 2 injections.
Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging.
Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide.
She had the injection of Omniscan - also known as gadodiamide - at Glasgow's Gartnavel Hospital in September 2006.
Patient 5 had received gadodiamide (Omniscan, GE Healthcare, Waukesha, Wisconsin), whereas the other 5 patients each had received gadopentetate dimeglumine (Magnevist, Bayer HealthCare Pharmaceuticals, Montville, New Jersey) as intravenous contrast during magnetic resonance studies.
Seven patients underwent MRI contrast administration; all received gadodiamide (Omniscan, GE Healthcare).
Nowack and Wachtler (2006) describe a patient's complaints of burning sensations and reddening of the lower and upper extremities one day after undergoing an MRA using gadodiamide (a gadolinium-based MRI contrast agent).